APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy (DMD) Therapeutics

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Selected research

Market Outlook & Growth Opportunities

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 173894070427 December 2025192 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Read the full market overview

This report provides an overview of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Duchenne Muscular Dystrophy (DMD) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market.

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type

Exondys

Emflaza

Translarna

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Duchenne Muscular Dystrophy (DMD) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Duchenne Muscular Dystrophy (DMD) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Duchenne Muscular Dystrophy (DMD) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Duchenne Muscular Dystrophy (DMD) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Duchenne Muscular Dystrophy (DMD) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Duchenne Muscular Dystrophy (DMD) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Duchenne Muscular Dystrophy (DMD) Therapeutics industry.

Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Duchenne Muscular Dystrophy (DMD) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Duchenne Muscular Dystrophy (DMD) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends Table 2. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers Table 3. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges Table 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company, Product Type & Application Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Exondys Table 15. Significant Companies of Emflaza Table 16. Significant Companies of Translarna Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Clinics Table 24. Significant Companies of Home Care Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Sarepta Therapeutics Company Information Table 41. Sarepta Therapeutics Business Overview Table 42. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 44. Sarepta Therapeutics Recent Development Table 45. PTC Therapeutics Company Information Table 46. PTC Therapeutics Business Overview Table 47. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 49. PTC Therapeutics Recent Development Table 50. Pfizer Company Information Table 51. Pfizer Business Overview Table 52. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 54. Pfizer Recent Development Table 55. Bristol-Myers Squibb Company Information Table 56. Bristol-Myers Squibb Business Overview Table 57. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 59. Bristol-Myers Squibb Recent Development Table 60. Italfarmaco Company Information Table 61. Italfarmaco Business Overview Table 62. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 64. Italfarmaco Recent Development Table 65. Santhera Pharmaceuticals Company Information Table 66. Santhera Pharmaceuticals Business Overview Table 67. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 69. Santhera Pharmaceuticals Recent Development Table 70. Research Programs/Design for This Report Table 71. Authors List of This Report Table 72. Secondary Sources Table 73. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Image Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Exondys Image Figure 8. Emflaza Image Figure 9. Translarna Image Figure 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Clinics Image Figure 15. Home Care Image Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Company
  1. 3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Product Type and Application
  6. 3.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Duchenne Muscular Dystrophy (DMD) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type
  1. 4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Type Introduction
  2. 4.1.1 Exondys
  3. 4.1.2 Emflaza
  4. 4.1.3 Translarna
  5. 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type
  6. 4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type (2021-2032)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
  1. 5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Home Care
  5. 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application
  6. 5.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application (2021-2032)
6 Duchenne Muscular Dystrophy (DMD) Therapeutics Regional Value Analysis
  1. 6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Duchenne Muscular Dystrophy (DMD) Therapeutics Country-level Value Analysis
  1. 7.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sarepta Therapeutics
  2. 8.1.1 Sarepta Therapeutics Company Information
  3. 8.1.2 Sarepta Therapeutics Business Overview
  4. 8.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  6. 8.1.5 Sarepta Therapeutics Recent Developments
  7. 8.2 PTC Therapeutics
  8. 8.2.1 PTC Therapeutics Company Information
  9. 8.2.2 PTC Therapeutics Business Overview
  10. 8.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  12. 8.2.5 PTC Therapeutics Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Italfarmaco
  26. 8.5.1 Italfarmaco Company Information
  27. 8.5.2 Italfarmaco Business Overview
  28. 8.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  30. 8.5.5 Italfarmaco Recent Developments
  31. 8.6 Santhera Pharmaceuticals
  32. 8.6.1 Santhera Pharmaceuticals Company Information
  33. 8.6.2 Santhera Pharmaceuticals Business Overview
  34. 8.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  36. 8.6.5 Santhera Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst